Last edition
News about
Harbour BioMed Publishes Positive Phase I Data for HBM9378 in Immunology
Harbour BioMed reports favourable safety and pharmacokinetic profile for HBM9378 in Phase I trial, supporting further development for severe immunological disorders.
DNP Establishes Second Overseas R&D Centre in India at IIT Hyderabad
DNP has established its second overseas R&D base at IIT Hyderabad, India, to accelerate the commercialisation of wireless power supply technologies for Active Pharmaceutical Ingredients (APIs) and Electric Vehicles (EVs), targeting growth opportunities in the Indian and African markets.
Belief Pharmaceuticals' Haemophilia B Gene Therapy Approved in Macau
Macau approves Belief Pharmaceuticals’ Popedacoq gene therapy for haemophilia B, marking regional expansion after China approval and advancing access to one-time treatment solutions.
Eveliqure and Serum Institute of India Partner to Develop Anti-Diarrhoeal Vaccines
Eveliqure and Serum Institute of India (SII) have partnered to develop anti-diarrhoeal vaccines, with Eveliqure set to receive an upfront payment, milestone-based earnings and royalties on net sales, while SII will lead development and global commercialisation.
Belief Pharmaceuticals Group has announced that its gene therapy BM-H901 injection (generic name: Popedacoq injection) has received approval from the Macau Drug Administration for treating adult patients with moderate to severe haemophilia B (congenital factor IX deficiency).
Sun Pharma Launches Semaglutide Injection in India Under Noveltreat and Sematrinity
Sun Pharmaceutical Industries has introduced semaglutide injections in India under the brands Noveltreat and Sematrinity, expanding access to advanced therapies for chronic weight management and type 2 diabetes. The launch strengthens treatment options with multiple dose strengths tailored to patient needs alongside diet and lifestyle interventions.
Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity
Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.
GI Innovation, Johnson & Johnson Partner for Phase Ib Trial in Advanced Prostate Cancer
GI Innovation enters clinical supply agreement with Johnson & Johnson to evaluate GI-102 and pasritamig combination therapy in metastatic castration-resistant prostate cancer patients.
Novo Nordisk Wins FDA Approval for Wegovy HD to Advance Obesity Treatment
FDA approves Novo Nordisk’s Wegovy HD (semaglutide 7.2 mg), a higher-dose weekly injection delivering significant weight loss, supported by strong Phase III trial outcomes.
Talzenna Plus Xtandi Improve Progression-Free Survival in Metastatic Prostate Cancer
Talzenna plus Xtandi significantly improved Progression-Free Survival (PFS) in the phase-III TALAPRO-3 trial, reducing the risk of disease progression or death in HRR-mutated Metastatic Prostate Cancer, with a positive trend in Overall Survival (OS).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy